Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AGTR2 | P50052 | 7/20 | 0.90 |
| ▸ | AGTR1 | P30556 | 4/20 | 0.90 |
| ▸ | REN | P00797 | 2/20 | 0.66 |
| ▸ | NTSR2 | O95665 | 1/20 | 0.66 |
| ▸ | NTSR1 | P30989 | 1/20 | 0.66 |
| ▸ | LNPEP | Q9UIQ6 | 3/20 | 0.65 |
| ▸ | ANPEP | P15144 | 1/20 | 0.65 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31332289 | 0.95 | AGTR2 (0.91) | AGTR2AGTR1RENNTSR2NTSR1 | |
| SCHEMBL29619824 | 0.95 | AGTR2 (0.94) | AGTR2AGTR1 | |
| Angiotensin Ii SCHEMBL29361852 | 0.95 | AGTR2 (1.00) | AGTR2AGTR1 | |
| Angiotensin Ii SCHEMBL21811603 | 0.95 | AGTR2 (1.00) | AGTR2AGTR1 | |
| Angiotensin Ii SCHEMBL1650427 | 0.95 | AGTR2 (1.00) | AGTR2AGTR1 | |
| SCHEMBL29394721 | 0.95 | AGTR2 (1.00) | AGTR2AGTR1 | |
| Angiotensin Ii SCHEMBL31477824 | 0.94 | AGTR2 (0.98) | AGTR2AGTR1 | |
| SCHEMBL29382642 | 0.93 | AGTR2 (0.78) | AGTR2AGTR1RENNTSR2NTSR1 | |
| Acetic Acid SCHEMBL34470176 | 0.93 | AGTR2 (0.83) | AGTR2AGTR1RENNTSR2NTSR1 | |
| SCHEMBL28485749 | 0.92 | AGTR2 (0.94) | AGTR2AGTR1NTSR2NTSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2026090251-A1 | METHODS FOR IMPROVING TREATMENT OUTCOMES IN PATIENTS UNDERGOING ULTRAFILTRATION | PROLETARIAT THERAPEUTICS, INC. (US) | 2026-04-30 | — | — | WO | claimed |
| US-20240426840-A1 | COMPOSITIONS AND METHODS FOR DETECTING AND TREATMENT OF MEMBRANOPROLIFERATIVE GLOMERULONEPHRITIS | TEXAS A & M UNIV SYS (US) | 2024-12-26 | — | — | US | claimed |
| WO-2026090251-A1 | METHODS FOR IMPROVING TREATMENT OUTCOMES IN PATIENTS UNDERGOING ULTRAFILTRATION | PROLETARIAT THERAPEUTICS, INC. (US) | 2026-04-30 | — | — | WO | disclosed |
| US-20260053430-A1 | VOICE-BASED MONITORING AND ALERTING FOR REMOTE DECOMPENSATED HEART FAILURE DETECTION | NOAH LABS GMBH (DE) | 2026-02-26 | — | — | US | disclosed |
| US-20260049331-A1 | Sense-and-Response of Proteins, Peptides, and Small Molecules Using Ligand-Induced Dimerization Activating RNA Editing (LIDAR) | UNIV LELAND STANFORD JUNIOR (US) | 2026-02-19 | — | — | US | disclosed |
| US-20250347677-A1 | BIOLOGICAL NANOPORES HAVING TUNABLE PORE DIAMETERS AND USES THEREOF AS ANALYTICAL TOOLS | UNIV GRONINGEN (NL) | 2025-11-13 | — | — | US | disclosed |
| US-20250223580-A1 | PROGRAMMABLE NUCLEASE-PEPTIDASE COMPOSITIONS | THE BROAD INSTITUTE, INC. | 2025-07-10 | — | — | US | disclosed |
| US-12336840-B2 | Voice-based monitoring and alerting for remote decompensated heart failure detection | NOAH LABS GMBH (DE) | 2025-06-24 | — | — | US | disclosed |
| US-20250179130-A1 | METHODS AND SYSTEMS FOR DESIGNING AND/OR CHARACTERIZING SOLUBLE LIPIDATED LIGAND AGENTS | ON TARGET THERAPEUTICS LLC | 2025-06-05 | — | — | US | disclosed |
| WO-2025046236-A1 | METHODS FOR NANOPORE-BASED ANALYTE DETECTION | PORTAL BIOTECH LIMITED (GB) | 2025-03-06 | — | — | WO | disclosed |
| US-20250000445-A1 | VOICE ANALYSIS TO PREDICT DECOMPENSATED HEART FAILURE | NOAH LABS GMBH (DE) | 2025-01-02 | — | — | US | disclosed |
| US-12060397-B2 | Soluble lipidated ligand agents for treating eye inflammation | TUFTS MEDICAL CENTER (US) | 2024-08-13 | — | — | US | disclosed |
| CN-116981697-A | Secreted payload modulation | 森迪生物科学公司 | 2023-10-31 | — | — | CN | disclosed |
| US-20230165790-A1 | NASAL FOAM VIA CRIBRIFORM PLATE FOR MEDICATION DELIVERY TO THE BRAIN AND/OR BODY AND FOR NASAL MOISTURIZATION AND HYGIENE | GUPTA SANJAY (US) | 2023-06-01 | — | — | US | disclosed |
| CN-112225713-B | Synthesis process of 5-hydroxybenzofuran compound | 华东理工大学 | 2023-02-28 | — | — | CN | disclosed |
| CN-111024960-B | Additive for detecting hypertension blood sample, kit and application | 广州阳普医疗科技股份有限公司 | 2023-02-17 | — | — | CN | disclosed |
| US-11576857-B2 | Nasal foam via cribriform plate for medication delivery to the brain and/or body and for nasal moisturization and hygiene | GUPTA SANJAY (US) | 2023-02-14 | — | — | US | disclosed |
| US-11559483-B2 | Nasal foam via cribriform plate for medication delivery to the brain and/or body and for nasal moisturization and hygiene | GUPTA SANJAY (US) | 2023-01-24 | — | — | US | disclosed |
| CN-114514032-A | Angiotensin type 2 (AT2) receptor agonists for the treatment of cancer | 兰提欧派普有限公司 | 2022-05-17 | — | — | CN | disclosed |
| US-20220135633-A1 | METHODS AND SYSTEMS FOR DESIGNING AND/OR CHARACTERIZING SOLUBLE LIPIDATED LIGAND AGENTS | ON TARGET THERAPEUTICS LLC | 2022-05-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220135633-A1 | METHODS AND SYSTEMS FOR DESIGNING AND/OR CHARACTERIZING SOLUBLE LIPIDATED LIGAND AGENTS | LDLR, HDLBP, LIPG | AGTR2 1051/4885AGTR1 1339/4885REN 3060/4885 |
| US-20260053430-A1 | VOICE-BASED MONITORING AND ALERTING FOR REMOTE DECOMPENSATED HEART FAILURE DETECTION | NPPA, NPR1, NPR3 | AGTR2 336/4885AGTR1 427/4885REN 570/4885 |
| US-20260049331-A1 | Sense-and-Response of Proteins, Peptides, and Small Molecules Using Ligand-Induced Dimerization Activating RNA Editing (LIDAR) | ADAR, ZFR, SLIRP | AGTR2 3417/4885AGTR1 3360/4885REN 4833/4885 |
| US-20250179130-A1 | METHODS AND SYSTEMS FOR DESIGNING AND/OR CHARACTERIZING SOLUBLE LIPIDATED LIGAND AGENTS | LDLR, HDLBP, LIPG | AGTR2 1051/4885AGTR1 1339/4885REN 3060/4885 |
| US-12060397-B2 | Soluble lipidated ligand agents for treating eye inflammation | LIPG, CD40, LDLR | AGTR2 601/4885AGTR1 850/4885REN 2001/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.